Free Trial

Twin Capital Management Inc. Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

Twin Capital Management Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,392 shares of the company's stock after selling 1,870 shares during the period. Johnson & Johnson comprises 1.0% of Twin Capital Management Inc.'s holdings, making the stock its 15th largest position. Twin Capital Management Inc.'s holdings in Johnson & Johnson were worth $8,855,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson in the 4th quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.2%

Shares of JNJ traded down $0.28 during mid-day trading on Wednesday, hitting $167.66. 3,702,658 shares of the company's stock were exchanged, compared to its average volume of 8,134,632. The company has a market cap of $403.39 billion, a PE ratio of 17.92, a P/E/G ratio of 2.09 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a 50-day simple moving average of $154.29 and a 200 day simple moving average of $155.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The business's quarterly revenue was up 5.8% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. UBS Group reiterated a "buy" rating and set a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Raymond James Financial reduced their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

Check Out Our Latest Stock Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines